United Therapeutics Corporation (NASDAQ: UTHR) Stock Analysis: Goldman Sachs Rating and Market Insights

• Goldman Sachs initiated coverage on United Therapeutics Corporation (NASDAQ: UTHR) with a "Sell" rating and a $321.00 price target, significantly below its current trading price.
• Despite the bearish outlook, a "buy" thesis exists, driven by the company's Tyvaso franchise and potential future drug approval catalysts.
• Recent insider selling and institutional stake reductions, coupled with the stock trading below its 50-day and 200-day moving averages, suggest potential downward pressure on the biotechnology stock.

United Therapeutics Corporation (NASDAQ: UTHR) is a leading biotechnology company focused on developing unique products for patients with chronic and life-threatening conditions. Operating within the pharmaceutical sector, the company specializes in developing innovative therapies for areas like pulmonary hypertension. With a robust market capitalization of around $20.77 billion, United Therapeutics stands as a notable player within its industry.

On September 24, 2026, Goldman Sachs analyst Andrea Newkirk set a price target of $321.00 for United Therapeutics, as highlighted by StreetInsider. This new target represents a significant 34.41% below the stock's price of $489.42 at the time of the report. The analysis from Goldman Sachs initiated coverage on the biotechnology stock with a "Sell" rating, impacting investor sentiment.

This bearish view, however, contrasts with other investment perspectives. A Seeking Alpha article notes that a "buy" thesis for United Therapeutics is largely based on its successful Tyvaso franchise and anticipated future catalysts. These events, such as upcoming PDUFA dates for crucial drug approvals, are expected by some market observers to drive significant growth and potentially increase the stock's value.

Recent market activity indicates some selling from key figures and institutions. CEO Martine Rothblatt sold 9,500 shares for a total of approximately $4.70 million, as reported by Defense World. Furthermore, Corient Private Wealth LP reduced its stake in United Therapeutics by a notable 35.9% during the second quarter, divesting 7,513 shares, signaling shifts in institutional investment.

United Therapeutics currently exhibits a price-to-earnings (P/E) ratio of 17.80, a key metric for stock valuation comparing its share price to its earnings per share. From a technical analysis perspective, the stock's 50-day moving average stands at $514.05, while its 200-day moving average is $540.51. The current price trading below both these significant levels suggests potential bearish momentum in its stock performance.